hypoglycemic Agents(metformin) — Competitive Intelligence Brief

hypoglycemic Agents(metformin) (hypoglycemic Agents(metformin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Endocrinology / Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain Endocrinology / Diabetes Small molecule

Target snapshot

hypoglycemic Agents(metformin) (hypoglycemic Agents(metformin)) — First Affiliated Hospital of Wenzhou Medical University. Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, thereby lowering blood glucose levels in type 2 diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
hypoglycemic Agents(metformin) TARGET	hypoglycemic Agents(metformin)	First Affiliated Hospital of Wenzhou Medical University	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Amlodipine plus Metformin	Amlodipine plus Metformin	Third Military Medical University	marketed	Combination therapy: calcium channel blocker + biguanide antidiabetic	L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)
Metformin and FSHr	Metformin and FSHr	Assistance Publique - Hôpitaux de Paris	marketed	Combination therapy: biguanide + gonadotropin receptor agonist	Metformin: mitochondrial glycerophosphate dehydrogenase; FSHr: follicle-stimulating hormone receptor
Liraglutide + metformin	Liraglutide + metformin	University Medical Centre Ljubljana	marketed	GLP-1 receptor agonist + biguanide combination	GLP-1 receptor; metformin targets mitochondrial glycerophosphate dehydrogenase
"Metformin" and "Mitiglinide"	"Metformin" and "Mitiglinide"	Third Affiliated Hospital of Third Military Medical University	marketed	Antidiabetic combination (biguanide + meglitinide)	Metformin: AMP-activated protein kinase (AMPK); Mitiglinide: ATP-sensitive potassium channel (KATP)
metformin, glyburide and glargine	metformin, glyburide and glargine	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin)	Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class